

Introduction and overall state of play of the Accreditation and Designation Programme

Simon Oberst, Director of Quality and Accreditation

Jean-Benoît Burrion, Chair, A&D Board



12th June 2024 0845, Helsinki Oncology Days



The OEI Network

The OEI Network

- ★ OEI Member A&D certified Comprehensive Cancer Network
- ★ OEI Member A&D certified Comprehensive Cancer Centre
- ★ OEI Member A&D certified Cancer Centre
- ★ OEI Member in the A&D process
- OEI Member



OUR PROGRAMME BY THE NUMBERS

34

Comprehensive Cancer Centres

19

Cancer Centres

2

Comprehensive Cancer Networks

26

Centres in accreditation

= 81

Centres and Networks in our programme



List of centres with Peer Reviews in 2024



**ACCREDITATION
AND
DESIGNATION
PROGRAMME**

1. IPO Lisbon, Lisbon, **Portugal**
2. Galway University Hospital, Galway, **Ireland**
3. Istituto Tumori, Giovanni Paolo II, Bari, **Italy**
4. Uppsala University Hospital, Uppsala, **Sweden**
5. Cancer Institute AP-HP. Nord – Université Paris Cité, Paris, **France**
6. Anadolu Medical Center, Anadolu, **Turkey**
7. Centre Jean Perrin, Clermont-Ferrand, **France**
8. Linköping University Hospital, **Sweden**
9. Karolinska University Hospital, Stockholm, **Sweden**
10. Fundación Instituto Valenciano de Oncología IVO, Valencia, **Spain**
11. Cork University Hospital/University College Cork, **Dublin**
12. Leuven Cancer Institute, Leuven, **Belgium**
13. Centre Paoli Calmette, Marseille, **France**
14. Riga East University Hospital, **Latvia**
15. Turku University Hospital, **Finland**
16. Erasmus, Rotterdam, **The Netherlands**
17. Clinical University of Navarra, Pamplona/Madrid, **Spain**
18. Institut Gustav Roussy, Paris, **France**
19. Tampere University Hospital, **Finland**
20. Trinity St James, Dublin, **Ireland**



1. Rijnstate (NL)
2. St Vincent (IRE)
3. Copenhagen (DK)
4. Aarhus (DK)
5. Lille (FR)
6. Bordeaux (FR)
7. Strassbourg (FR)
8. Montpellier (FR)
9. HUB, Barcelona (SP)
10. Tarragona (SP)
11. San Matteo, Pavia (IT)
12. ASST Spedali Civili, Brescia (IT)



- The last few years have seen big growth in France, Sweden and Ireland
- Now we see considerable interest in Spain, Denmark, The Netherlands, Slovakia, and others...
- We are looking beyond Europe – e.g. South America



Two OECD Auditors' Training Courses are underway

101

Active Auditors



10-12 March 2024
Inveruno, Italy
18 participants

Autumn 2024
Inveruno, Italy
18 participants



Auditors



Group Composition

In the A&D Programme: 101 active Auditors:

- Chairs (Directors)
- Nurses / Nurse background
- Quality Managers
- Physicians
- Research background
- Other (pharmacy, psychologist)

In the A&D Programme: 101 active Auditors

- 11 Cancer Centre Directors
- 23 Nurses / Nurse background
- 20 Quality Managers
- 26 Physicians
- 18 Research background
- 3 other

Therefore – emphasis on training and refreshment about our processes

➤ We will be recruiting more auditors for a March 2024 training



- CCI4EU (OEI coordinating): federating 55 partners: Capacity Building in Comprehensive Cancer Infrastructures (CCIs)
 - Full talk tomorrow
 - Mobilisation of around 100 subject experts
 - 9 CCIs will be chosen for a 'Deep Dive' tailored intervention
 - 3 years; €10 million; proof of concept
 - Focus on research and innovation in cancer
 - This is resource-intensive for OEI
- DG Reform Latvia (fuller talk this morning): Advising on a roadmap to create a Comprehensive Cancer Infrastructure in Latvia
 - 3 consultants
 - Major data gathering
 - 4 2-day site visits
 - Report and recommendations





Who?

The Accreditation Board

- Jean-Benoit Burrion, Belgium, Chair
- Mef Nilbert, Sweden, Vice Chair
- Jozsef Lövey, Norway
- Eva Jolly, Sweden
- Peter Nagy, Hungary
- John Reynolds, Ireland
- Vanesa Gregorc, Italy
- ❖ We will be recruiting more members of the Board

In attendance:

Simon Oberst, Director of Quality and Accreditation

Wim van Harten, The Netherlands

IKNL coordinators



Who?

The Accreditation Committee

- Jozsef Lovey, Norway, Chair
- Claire Noonan, Ireland
- David Verger, France
- Hisam Alahdab, Qatar and Turkey
- Marek Svoboda, Czech
- Jorrit Enserink, Norway
- Mari-Leen Pärn, Estonia
- Mark Fogarty, Ireland
- Outi Nikunen, Finland
- Patricia Doherty, Ireland
- ❖ We will be recruiting more members of the Committee

In attendance:




Who?

The Accreditation coordinators

- Harriet Blaauwgeers, Manager
- Willien Westerhuis
- Jolanda van Hoeve
- Wendy Dontje
- Hilde Dijker
- Janneke Verloop

- ❖ Secretary: Mushanga Holtvoort
- ❖ Liaison: Roxana Plesoianu

The OECI standards revision process



- 1) When the A&D Board has completed its reviews (estimated by September 2024) send the Draft Standards to OEI Member representatives for feedback and comment.
- 2) On 7th October 2024 a 3 hour VC focused on Research aspects with invited representatives of member Centres to consider how best to evaluate Clinical Trials and Translational Research. This VC is being co-chaired by Prof Josep Taberero and Prof Mef Nilbert.
- 3) The regular 5-year consultation with Professional cancer organisations in Europe which will take place in person on 10-11 December 2024 in Brussels. This will also include members of the OEI Board and invited representatives from ESMO, ESTRO, ESSO, EONS, ECL, EPOS, ERO etc, and hopefully representatives from ASCO and NCCN in the United States. This event is designed for input but also to demonstrate the A&D capabilities to a wider audience.
- 4) Final drafts and approval processes by the A&D Board and OEI Board in Spring 2025. Drafting of the new Manual 4.0 and Launch at the Oncology Days 2025.



- ❖ OEI wants to assist University Hospitals, and other hospitals, to form themselves into Comprehensive Cancer Centres with good governance and organisation.
- ❖ This may require new governance and organisational structures, working agreements with Universities and free-standing research institutes
- ❖ The Comprehensive Cancer Centre model can be public or private, or even a mixture of the two
- ❖ The emphasis should be on practical workability and integration, not necessarily requiring a separate legal entity



Governance & Organisation of Cancer Centres

Guidance Note on Requirements for Governance Structures of Cancer Centres which will comply with OECD Standards

Written by the Accreditation & Designation Board of OECD

Introduction

Cancer centres are designed to bring together leading clinical expertise across all major cancer types with translational cancer research and education, thus accelerating adoption of novel therapies and enrolment in clinical trials.

Most fundamental is the centre's multidisciplinary character, and its governance as an identifiable entity, often within a larger structure. Standalone cancer centres - founded to treat cancer patients and perform cancer-focused research - generally have a more simple corporate structure.

Increasingly, cancer centres and comprehensive cancer centres are being developed within University Hospitals treating all health conditions, and with their partner Universities pursuing all forms of health research.

It is in particular to help define effective governance structures in University Hospitals that this Guidance Note is written, in order to fulfil OECD Standards.



MORE AT:
OECD.EU/ACCREDITATION



Guidance

The Guidance which follows is intended to assist you in the development of your cancer centre. It will be your decision how to adopt this guidance.



ACCREDITATION AND DESIGNATION



Requirements in order to fulfil the Standards

- 1 To have established a clear description of the role, mandate and accountabilities of a (Comprehensive) Cancer Centre Board, which encompasses all aspects of the cancer care pathway and all forms of cancer research. It should define how the (University) Hospital(s) and the University(ties) work together in cancer.

The (Comprehensive) Cancer Centre Board should own the cancer strategy in the location of the cancer centre, and supervise the overall performance and quality of the cancer centre.

In most cases it is the existence and functioning of this Board which demonstrates that the Cancer Centre is an identifiable entity - not necessarily a legal entity - an organisation whose members and member institutions work together through agreements, shared resources, and a unified strategy which binds together cancer care, research and education.

Governance models are generally more simple in the case of specialist Cancer Hospitals, but in the context of University Hospitals treating all diseases, the situation is naturally more complex.

We provide in an appendix three possible models of a Cancer Centre Board in the context of a University Hospital(s) and a partner University (or Universities) and/or research institutes, which would fulfil OECD Standards.

For success, all models suggest that on the hospital side, there is a Board which brings together all the main modalities of diagnosis, treatment and care: radiology, pathology, radiotherapy, systemic therapies, surgery, supportive and palliative care.

In addition, the Board should have representation with senior responsibility for clinical quality assurance.

All models also suggest on the research side a Board which brings together all aspects of cancer research, including all cancer relevant basic and translational science pursued at the university and other institutes.

Clinical research is generally a shared responsibility between the hospital and research institute(s).

The balance of clinical and scientific representation on the main (Comprehensive) Cancer Centre Board will differ according to context. But the key to the whole is the integration of clinical and research leadership in cancer in a single cancer-specific Board.

Model 1

The leadership of the (Comprehensive) Cancer Centre Board predominantly lies with senior Clinical leadership, but it is vital that key leaders of the cancer research community are also represented.

Model 2


(less common)

The leadership of the (Comprehensive) Cancer Centre Board predominantly lies with the research leadership, and it is vital that key leaders of the clinical cancer research community are also represented.

Model 3

This model has a Clinical Cancer Operational Board for the hospital(s), a Cancer Research/Teaching Board, and an overarching (Comprehensive) Cancer Centre Board bringing the key representatives of the other Boards together.





- The strengths of the accredited centres have been documented in the audit reports
- From these, 22 Excellent Practices in many different domains of care have been documented from around our centres
- The sharing of this material for the benefit of the OECI community is part of the vision and mission of the OECI A&D Programme.

1. Expanding the OEI quality and A&D community (within Europe, and beyond)
 - ✓ Our first peer reviews in South America
2. Creating more of a sense of community: spreading excellent practices; offering benchmarking; proposing support
 - ✓ Second round of excellent practices next year
3. Developing a 'toolbox' for Centres' development and accreditation
 - ✓ Patient pathways
 - ✓ Strategy documents (Centre and Research)
4. Developing Capacity Building capabilities (CCI4EU)
5. Liaising with the development of EUNetCCC – full talk and discussion tomorrow
6. The roll-out of Network accreditations following the ONCOZON pilot and applying the principles in SE; NL; FL; IR; FR; IT.
7. Continuing to build ties with ASCO, NCCN and NCI in the United States to boost the international recognition of our programme.



- ❖ We want to develop and improve what is distinctive about our quality and accreditation programme:
 - We believe in peer reviews, not technical audits
 - Our auditors are all professionals in Cancer Centres from day to day
 - Our programme is voluntary, not regulatory
 - We are enabling, not controlling
 - We can order our affairs and programme as our member experts and scientific findings demonstrate are best standards and practices
 - We want to be an effective community of practice where we enable each centre to improve, develop and learn from each other.



Thank you for your attention

